Results 291 to 300 of about 456,743 (411)

Antihypertensive Action of a Non-Sulfhydryl Angiotensin Converting Enzyme Inhibitor (CV-3317) in Various Hypertensive Models

, 1986
Yoshiyuki Inada, Masao J. Tanabe, Yumiko Shibouta, K Kawazoe, Kohei Nishikawa, Shintaro Kikuchi   +5 more
openalex   +1 more source

Neurokinin B is hydrolysed by synaptic membranes and by endopeptidase‐24.11 (‘enkephalinase’) but not by angiotensin converting enzyme [PDF]

, 1985
Nigel M. Hooper, Anthony J. Turner
openalex   +1 more source

Radiotracers for Molecular Imaging of Angiotensin-Converting Enzyme 2. [PDF]

Int J Mol Sci
Xu W, Langhans SA, Johnson DK, Stauff E, Kandula VVR, Kecskemethy HH, Averill LW, Yue X.   +7 more
europepmc   +1 more source

Role for inflammatory markers in predicting right ventricular failure in mechanical assist device recipients

ESC Heart Failure, EarlyView.
Abstract Right ventricular failure (RVF) is a common complication following left ventricular assist device (LVAD) implantation and increases patient morbidity and mortality. Due to the complex and limited understanding of RVF pathophysiology, efforts to prognosticate RVF after LVAD have been challenging.
Abdul‐Fatawu Osman, Shane S. Scott, Ebubechukwu O. Ezeh, Evans Osuji, Israel O. Ailemen, Mohamed H. Derbala, Salil Kumar, Asvin M. Ganapathi, Daniel B. Sims, Ashrith Guha, Bryan A. Whitson, Sakima A. Smith   +11 more
wiley   +1 more source

Angiotensin-converting enzyme 2 and hepatic SARS-CoV-2 infection: Regulation, association, and therapeutic implications. [PDF]

World J Gastroenterol
Luo YW, Huang AL, Tang KF.
europepmc   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects. [PDF]

, 1987
CM Dixon, RW Fuller, Peter J. Barnes
openalex   +1 more source

Angiotensin-converting enzyme in innate and adaptive immunity

Nature Reviews Nephrology, 2018
K. Bernstein, Z. Khan, J. Giani, Duo-Yao Cao, E. Bernstein, Xiao Z. Shen   +5 more
semanticscholar   +1 more source

Angiotensin-Converting Enzyme (ACE)-Inhibitor Activity of Novel Peptides Derived from Porcine Liver and Placenta. [PDF]

Molecules
Pearman NA, Morris GA, Smith AM.
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source